×

Biotech and Pharmaceuticals Medicine

  • March 22- Ultragenyx Pharmaceutical Inc said its drug to treat patients with seizures did not meet the main goal in a mid-stage study, sending its shares down 6.2 percent in after-market trading on Wednesday. The company said the study did not show statistical significance in reducing the frequency of seizures among patients treated with the drug compared to...

  • BOSTON— The former head of a Massachusetts pharmacy was acquitted Wednesday of murder allegations but convicted of racketeering and other crimes in a meningitis outbreak that was traced to fungus-contaminated drugs and killed 64 people across the country. Indiana, Michigan and Tennessee were hit hardest. Joan Peay, 76, of Nashville, Tennessee, suffered two...

  • *Trial failure trims Novartis blockbuster hopefuls to 12. *Some traders say failed drug had $2 bln/ year potential. ZURICH, March 22- Novartis's heart failure drug serelaxin flopped in a late-stage trial by not cutting cardiovascular death or slowing disease progression, marking the likely demise of a drug hopeful the Swiss firm had promoted as a potential...

  • ZURICH, March 22- Novartis' efforts to expand its heart treatment franchise beyond its flagship Entresto business suffered a blow when it announced on Wednesday its acute heart failure drug serelaxin had failed in a late-stage trial. Serelaxin, once seen a potential blockbuster, suffered a string of setbacks in 2014 when European Union health regulators and...

  • TRENTON, N.J.— U.S. regulators have approved the first new drug in a decade for Parkinson's disease, a chronic neurological disorder that causes tremors and movement difficulties. The Food and Drug Administration said Tuesday that it has approved Xadago for use when a patient's regular medicines aren't working well. According to the FDA, adding Xadago to...

  • Biogen wins patent decision

    CNBC's Meg Tirrell reports on the victory for Biogen in its patent case over its Multiple Sclerosis drug.

  • *Trial positive despite negative interim data. *To submit marketing application for mono, combo therapy in 2017. March 20- Eli Lilly and Co's combination of its experimental breast cancer drug and another widely used treatment slowed disease progression in patients who relapsed or did not benefit enough when treated with the anti-estrogen therapy.

  • *Co to discuss next steps with FDA, looks for strategic partner. The company's stock jumped about 19 percent to $19.50 in premarket trading on Monday. Everyday, 91 Americans die of opioid overdose, the U.S. Centers for Disease Control and Prevention estimates.

  • March 20- Nektar Therapeutics said its experimental opioid, designed to achieve pain relief without the high levels of euphoria that can lead to abuse and addiction with existing opioids, succeeded in a key late-stage study. U.S. regulators and lawmakers have taken a number of steps to control the supply of opioids as the country is engulfed in an epidemic of...

  • Abemaciclib, which was granted U.S. Food and Drug Administration breakthrough therapy status for breast cancer in 2015, is also being tested for use in lung cancer. After skin cancer, breast cancer is the most common cancer in women in the United States, according to the U.S. Centers for Disease Control and Prevention. About 40,610 women will die from breast...

  • March 20- Eli Lilly and Co said a combination of its experimental breast cancer drug and another widely used treatment slowed disease progression in a key study in patients who had relapsed or did not derive enough benefit from anti-estrogen therapy. Lilly's drug, abemaciclib, is from the same new class of breast cancer treatments as Pfizer Inc's recently...

  • March 20- U.S. drugmaker Eli Lilly and Co said on Monday a combination of its experimental breast cancer drug and chemotherapy slowed disease progression in patients who had relapsed or did not derive enough benefit from prior treatment.

  • WASHINGTON, March 17- Amgen Inc's $14,000 cholesterol drug Repatha cut the risk of heart attack and stroke by over 20 percent in patients with heart disease, but results from a highly anticipated study fell short of investor expectations and shares dropped 6 percent. Amgen acknowledged during a presentation for investors that it is already selling Repatha at...

  • WASHINGTON, March 17- Amgen Inc's $14,000 cholesterol drug Repatha cut the risk of heart attack and stroke by over 20 percent in patients with heart disease, but results from a highly-anticipated study fell short of investor expectations and shares dropped 6 percent. Sales of Repatha, and its competitor Praluent from Regeneron Pharmaceuticals and Sanofi,...

  • WASHINGTON, March 17- A long-acting new type of drug being developed by Medicines Co cut levels of "bad" LDL cholesterol in half in high-risk heart patients with no serious safety issues, according to data from a Phase II trial presented on Friday. Despite the positive results, Medicine Co shares fell 14.6 percent after highly-anticipated data from Amgen Inc's...

  • WASHINGTON, March 17- Amgen Inc's cholesterol drug Repatha cut the risk of heart attacks and strokes by over 20 percent in patients with heart disease, but the extent of its benefits in the highly-anticipated study disappointed investors and shares fell 6 percent. Sales of Repatha, and its competitor Praluent from Regeneron Pharmaceuticals and Sanofi, have...

  • WASHINGTON, March 17- Amgen Inc's cholesterol drug Repatha cut the risk of heart attacks and strokes by over 20 percent in patients with heart disease, but the extent of its benefits in the highly-anticipated study disappointed investors and shares fell 6 percent. Sanofi shares closed down 0.5 percent in Paris. Steve Miller, Chief Medical Office of Express...

  • WASHINGTON, March 17- Amgen Inc's Repatha drug cut the risk of heart attacks and strokes by over 20 percent in patients with heart disease, demonstrating a clinical benefit beyond its ability to slash "bad" LDL cholesterol levels, data from a huge study known as Fourier showed on Friday. Sanofi shares were down 1 percent in Paris. It remains to be seen whether results...

  • A long-acting cholesterol medicine cut the risk of having a heart attack or some other serious problems by 15 to 20 percent in a big study that's likely to spur fresh debate about what drugs should cost. It costs more than $14,000 a year, and insurers have balked at paying without proof that it lowers heart risks, not just the cholesterol number.

  • WASHINGTON, March 17- Amgen Inc's Repatha drug cut the risk of heart attacks and strokes by over 20 percent in patients with heart disease, demonstrating a clear clinical benefit beyond its ability to slash "bad" LDL cholesterol levels, data from a huge study known as Fourier showed on Friday. Results from the highly anticipated 27,564- patient Fourier study...